



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-Human Cytokeratin 8 [1E8-C6-B4] Standard Size Ab02687-10.0

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Human IgG1, Kappa

Clone Number: 1E8-C6-B4

Alternative Name(s) of Target: K8; Cytokeratin 8; CK 8; 1E8; Keratin, type II cytoskeletal 8; Keratin-8; Type-II keratin Kb8; 1E8

UniProt Accession Number of Target Protein: P05787

Published Application(s): WB, IP, IF

Published Species Reactivity: Human

Immunogen: The original antibody was generated by immunizing mice against the C-terminus (amino acids 472-483) of human Cytokeratin 8.

Specificity: The antibody is specific for the C-terminus of cytokeratin 8, one member of a diverse group of proteins called intermediate filament proteins. These proteins are often expressed in pairs. Cytokeratin 8 pairs with Cytokeratin 18 to form a component of the cytoskeleton in simple epithelial cells. Cytokeratin 8 is present on the surface of intact hepatocytes, hepatocellular carcinoma cells, and breast cancer cells.

Application Notes: The original antibody detected CK 8 by western blot from BT20 breast cancer cells. Immunofluorescence was performed on BT20 cells using this antibody, showing the carboxyl terminus of CK 8 was exposed on the surfaces of breast cancer cells. The Fab fragment of the antibody was used for inhibition experiments on breast cancer cell lines BT20, MDA-MB-157, MCF-7 and purified CK 8. Results showed a decreased plasminogen binding in all the experiments. The Fab fragment was used to study the role of cell-surface CK 8 in promoting the activation of plasminogen by t-PA in MCF-7 cells; preincubation of MCF-7 cells with the Fab fragment caused a concentration-dependent decrease in the ability of the cell cultures to promote plasminogen activation (Hembrough et al, 1996; pmid:8810346).

Antibody First Published in: Hembrough et al. Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator J Biol Chem. 1996 Oct 11;271(41):25684-91. [PMID:8810346](https://pubmed.ncbi.nlm.nih.gov/8810346/)

Note on publication: The paper describes the generation and characterization of an antibody against cytokeratin 8 for the purpose of defining its immunological, cellular, and biochemical characteristics.

Product Form

Size: 200 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.